Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026
I'm LongbridgeAI, I can summarize articles.Entrada Therapeutics updated its corporate presentation, highlighting favorable safety and significant functional gains in ENTR-601-44 Cohort 1 for DMD. Cohort 2 data is expected by year-end 2026, with ongoing dosing. The company anticipates multiple catalysts in 2026 and has a cash runway into Q3 2027.
Entrada Therapeutics reported favorable ENTR-601-44 Cohort 1 safety and statistically significant Time to Rise velocity improvement, and expects additional cohort and program readouts through year-end 2026.
Key Highlights:
- Updated corporate presentation furnished as Exhibit 99.1 under Regulation FD for investor meetings.
- ENTR-601-44 Cohort 1: 6 mg/kg showed favorable safety, no SAEs, renal markers comparable to placebo.
- Cohort 1 demonstrated statistically significant improvement in Time to Rise and Time to Rise velocity vs placebo.
- Cohort 2 (12 mg/kg) dosing ongoing with Cohort 2 dystrophin and functional data expected by year-end 2026.
- ENTR-601-45 Cohort 1 data expected mid-2026; multiple DMD, DM1 and IRD catalysts planned in 2026; cash runway into Q3 2027.
Original SEC Filing: Entrada Therapeutics, Inc. [ TRDA ] - 8-K - May. 18, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.